Novo Nordisk partners with OpenAI
Novo Nordisk announced a broad partnership with OpenAI aimed at using AI across its drug‑development pipeline, from data analysis to commercial operations. The market reacted positively in premarket trading after the tie‑up was disclosed (cnbc.com; bloomberg.com). Separately, regulators have approved a new 7.2mg Wegovy dose in the UK and the FDA has approved oral semaglutide as the first GLP‑1 pill for weight loss in the U.S., moves that expand product options even as pricing and demand dynamics remain under pressure (gurufocus.com; ajmc.com).
Novo Nordisk said Tuesday it is partnering with OpenAI to use artificial intelligence across the company, from finding drugs to running commercial teams. (cnbc.com) The Danish drugmaker said the deal will apply OpenAI tools globally across drug discovery, development, manufacturing and operations, with workforce training included. Novo Nordisk and OpenAI did not disclose financial terms. (biospace.com) Novo Nordisk shares rose in premarket trading after the announcement, and Bloomberg reported the company is adding the tie-up to earlier artificial intelligence work, including a research deal with Nvidia announced last year. (marketwatch.com; bloomberg.com) Drug development starts with sorting huge volumes of lab results, patient records and trial data to decide which compounds to test next. Artificial intelligence systems are being pitched as software that can scan those datasets faster, flag patterns and help researchers narrow choices before expensive human trials begin. (cnbc.com; bloomberg.com) Novo Nordisk is making that bet while defending its lead in obesity drugs. On April 14, the United Kingdom’s Medicines and Healthcare products Regulatory Agency approved a single-dose 7.2 milligram Wegovy pen for adults with obesity and a body mass index of 30 or higher. (gov.uk) The new United Kingdom device matters because patients previously had to take three separate 2.4 milligram injections to reach a 7.2 milligram weekly dose. Novo Nordisk said the newly approved pen delivers that maintenance dose in one injection. (gov.uk; pharmiweb.com) In the United States, the Food and Drug Administration approved Wegovy pill in December 2025 as the first oral glucagon-like peptide-1 treatment for chronic weight management, according to Novo Nordisk and coverage from The American Journal of Managed Care. That gave Novo Nordisk a pill option in a market built largely on weekly injections. (prnewswire.com; ajmc.com) Competition is tightening at the same time. Managed Healthcare Executive reported last week that Eli Lilly’s oral glucagon-like peptide-1 drug, orforglipron, won Food and Drug Administration approval for obesity and will be sold as Foundayo. (managedhealthcareexecutive.com) Novo Nordisk said the OpenAI partnership includes strict data governance and human oversight, language that reflects how drugmakers are trying to speed decisions without handing regulatory or medical judgment entirely to software. The next test is whether faster internal workflows translate into new obesity drugs that can hold share against Eli Lilly and newer pill rivals. (biospace.com; bloomberg.com)
